Geode Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-126,959
| Closed | -$78K | – | 4232 |
|
|
2018
Q4 | $78K | Hold |
126,959
| – | – | ﹤0.01% | 3908 |
|
|
2018
Q3 | $165K | Sell |
126,959
-584
| -0.5% | -$907 | ﹤0.01% | 3808 |
|
|
2018
Q2 | $172K | Sell |
127,543
-66,832
| -34% | -$102K | ﹤0.01% | 3762 |
|
|
2018
Q1 | $281K | Buy |
194,375
+500
| +0.3% | +$1.04K | ﹤0.01% | 3592 |
|
|
2017
Q4 | $436K | Buy |
193,875
+12,193
| +7% | +$30.9K | ﹤0.01% | 3413 |
|
|
2017
Q3 | $617K | Buy |
181,682
+8,278
| +5% | +$27.8K | ﹤0.01% | 3288 |
|
|
2017
Q2 | $615K | Buy |
173,404
+7,194
| +4% | +$23.7K | ﹤0.01% | 3284 |
|
|
2017
Q1 | $565K | Buy |
166,210
+4,684
| +3% | +$18.2K | ﹤0.01% | 3265 |
|
|
2016
Q4 | $743K | Buy |
161,526
+14,139
| +10% | +$58.3K | ﹤0.01% | 3124 |
|
|
2016
Q3 | $624K | Buy |
147,387
+58,353
| +66% | +$189K | ﹤0.01% | 3162 |
|
|
2016
Q2 | $213K | Buy |
89,034
+13,459
| +18% | +$48.7K | ﹤0.01% | 3568 |
|
|
2016
Q1 | $355 | Hold |
75,575
| – | – | ﹤0.01% | 3403 |
|
|
2015
Q4 | $297K | Buy |
75,575
+1,140
| +2% | +$5.25K | ﹤0.01% | 3511 |
|
|
2015
Q3 | $288K | Buy |
+74,435
| New | +$342K | ﹤0.01% | 3513 |
|
Geode Capital Management's AST Position: Q1 2019 in Review
Geode Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 126,959 shares — an estimated $78K sold.
Geode Capital Management first reported a position in AST in Q3 2015 and held it in 14 quarters. The position peaked at $743K in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Geode Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Geode Capital Management sold 126,959 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $78K.
- Geode Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 14 quarters.
- Geode Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $743K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Geode Capital Management's 13F filing for Q1 2019, filed 14 May 2019.